Viking Therapeutics (VKTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.10
- EPS estimate
- −$1.11
- EPS surprise
- +0.72%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Jul 29, 2026
Viking Therapeutics reported Q2 2026 results on July 29, 2026. It posted a loss of $1.10 per share, slightly narrower than the expected loss of $1.11, a 0.72% beat. The table gives no revenue figures or revenue estimates. Against Q2 2025, the loss per share nearly doubled from $0.58, up about 90%.
Every quarter in the table is a loss, and losses have grown. From Q3 2021 through Q4 2024, the quarterly loss stayed between $0.16 and $0.32 per share. It then widened each quarter through Q4 2025, when it reached $1.38, the largest here. The annual loss was $0.91 per share in 2022, $0.92 in 2023, $1.00 in 2024 and $3.18 in 2025. The first half of 2026 shows a $2.47 loss, against $0.99 a year earlier. Viking beat the EPS estimate in 9 of the last 20 quarters. Q2 2026 ended a run of six straight misses.
Viking reported Q3 results between October 22 and November 3 in each of the past five years, with the last four in late October. That points to late October 2026 for the next report. It will show whether the loss keeps narrowing from the Q4 2025 peak.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$1.11 | −$1.10 | +0.72% | $0.00 | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.98 | −$1.37 | −40.43% | $0.00 | SEC |
| Q4 2025 | Feb 11, 2026 | −$0.90 | −$1.38 | −53.81% | $0.00 | SEC |
| Q3 2025 | Oct 22, 2025 | −$0.71 | −$0.81 | −14.15% | $0.00 | SEC |
| Q2 2025 | Jul 23, 2025 | −$0.45 | −$0.58 | −29.90% | $0.00 | SEC |
| Q1 2025 | Apr 23, 2025 | −$0.33 | −$0.41 | −25.00% | $0.00 | SEC |
| Q4 2024 | Feb 5, 2025 | −$0.28 | −$0.32 | −15.98% | $0.00 | SEC |
| Q3 2024 | Oct 23, 2024 | −$0.24 | −$0.22 | +9.43% | $0.00 | SEC |
| Q2 2024 | Jul 24, 2024 | −$0.26 | −$0.20 | +23.84% | $0.00 | SEC |
| Q1 2024 | Apr 24, 2024 | −$0.28 | −$0.26 | +6.04% | $0.00 | SEC |
| Q4 2023 | Feb 7, 2024 | −$0.25 | −$0.25 | +1.57% | $0.00 | SEC |
| Q3 2023 | Oct 25, 2023 | −$0.22 | −$0.23 | −5.02% | $0.00 | SEC |
| Q2 2023 | Jul 26, 2023 | −$0.19 | −$0.19 | +1.40% | $0.00 | SEC |
| Q1 2023 | Apr 26, 2023 | −$0.24 | −$0.25 | −4.08% | $0.00 | SEC |
| Q4 2022 | Feb 8, 2023 | −$0.23 | −$0.26 | −11.92% | $0.00 | SEC |
| Q3 2022 | Oct 26, 2022 | −$0.23 | −$0.21 | +9.87% | $0.00 | SEC |
| Q2 2022 | Jul 27, 2022 | −$0.21 | −$0.23 | −8.49% | $0.00 | SEC |
| Q1 2022 | Apr 27, 2022 | −$0.19 | −$0.21 | −9.38% | $0.00 | SEC |
| Q4 2021 | Feb 9, 2022 | −$0.19 | −$0.16 | +14.44% | $0.00 | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.21 | −$0.17 | +19.05% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Viking Therapeutics (VKTX) last report earnings?
Viking Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did VKTX beat earnings estimates?
Yes. Viking Therapeutics reported EPS of −$1.10 for Q2 2026 against a −$1.11 estimate — a 0.72% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.